How can we improve oral contraceptive success in obese women?

Ganesh Cherala; Alison Edelman

doi:10.1586/17512433.2015.974558

How can we improve oral contraceptive success in obese women?

Ganesh Cherala, Alison Edelman

Obstetrics & Gynecology

Research output: Contribution to journal › Review article › peer-review

Abstract

A rapid increase in obesity rates worldwide further underscores the importance of better understanding the pharmacokinetic alterations in this sub-population and the subsequent effects on pharmacotherapeutics. Pharmacokinetics of contraceptive steroids is altered in obese oral contraceptive users, which may in turn impact efficacy. Our study has identified several dosing strategies that offset these pharmacokinetic changes and may improve effectiveness for obese oral contraception users.

Original language	English (US)
Pages (from-to)	1-3
Number of pages	3
Journal	Expert Review of Clinical Pharmacology
Volume	8
Issue number	1
DOIs	https://doi.org/10.1586/17512433.2015.974558
State	Published - Jan 1 2014

Keywords

drug failure
obesity
oral contraception
pharmacokinetics
steroidal hormones

ASJC Scopus subject areas

Pharmacology, Toxicology and Pharmaceutics(all)
Pharmacology (medical)

Access to Document

10.1586/17512433.2015.974558

Cite this

@article{b853f41e3c834972a62ba9c85dcd1e04,

title = "How can we improve oral contraceptive success in obese women?",

abstract = "A rapid increase in obesity rates worldwide further underscores the importance of better understanding the pharmacokinetic alterations in this sub-population and the subsequent effects on pharmacotherapeutics. Pharmacokinetics of contraceptive steroids is altered in obese oral contraceptive users, which may in turn impact efficacy. Our study has identified several dosing strategies that offset these pharmacokinetic changes and may improve effectiveness for obese oral contraception users.",

keywords = "drug failure, obesity, oral contraception, pharmacokinetics, steroidal hormones",

author = "Ganesh Cherala and Alison Edelman",

note = "Funding Information: This study was supported by grant support from National Institutes of Health [R03 HD053611 NICHD], the office of women{\textquoteright} s health and the National Institutes of Health [Building Interdisciplinary Research Career in Women{\textquoteright} s Health – 2K12HD043488 NICHD], the OHSU Oregon Clinical & Translational Research Institute [NIH NCRR 1 UL1 RR024120], and the Bioanalytical Shared Resource/Pharmacokinetics Core at OHSU. A Edelman is a consultant for Gynuity Health Projects, WHO, CDC, Genzyme, and Agile Therapeutics; trainer for Merck & Co. and author for UptoDate (Royalties received). These potential conflicts of interest have been reviewed and managed by OHSU. Edelman is a consultant for Gynuity Health Projects, WHO, CDC, Genzyme, and Agile Therapeutics; trainer for Merck & Co.; and author for UptoDate (Royalties received). These potential conflicts of interest have been reviewed and managed by OHSU. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",

year = "2014",

month = jan,

day = "1",

doi = "10.1586/17512433.2015.974558",

language = "English (US)",

volume = "8",

pages = "1--3",

journal = "Expert Review of Clinical Pharmacology",

issn = "1751-2433",